Mastrangelo MJ - Search Results

1

Immunopotentiation with low-dose cyclophosphamide in the active specific immunotherapy of cancer.

Bass KK, Mastrangelo MJ. Bass KK, et al. Among authors: mastrangelo mj. Cancer Immunol Immunother. 1998 Sep;47(1):1-12. doi: 10.1007/s002620050498. Cancer Immunol Immunother. 1998. PMID: 9755873 Review.

2

Effect of the dose and composition of an autologous hapten-modified melanoma vaccine on the development of delayed-type hypersensitivity responses.

Berd D, Sato T, Mastrangelo MJ. Berd D, et al. Among authors: mastrangelo mj. Cancer Immunol Immunother. 2002 Aug;51(6):320-6. doi: 10.1007/s00262-002-0285-3. Epub 2002 Jun 6. Cancer Immunol Immunother. 2002. PMID: 12111120 Clinical Trial.

3

Tumor-derived interleukin-10 as a prognostic factor in stage III patients undergoing adjuvant treatment with an autologous melanoma cell vaccine.

Mahipal A, Terai M, Berd D, Chervoneva I, Patel K, Mastrangelo MJ, Sato T. Mahipal A, et al. Among authors: mastrangelo mj. Cancer Immunol Immunother. 2011 Jul;60(7):1039-45. doi: 10.1007/s00262-011-1019-1. Epub 2011 Apr 26. Cancer Immunol Immunother. 2011. PMID: 21519827

4

Effect of low dose cyclophosphamide on the immune system of cancer patients: depletion of CD4+, 2H4+ suppressor-inducer T-cells.

Berd D, Mastrangelo MJ. Berd D, et al. Among authors: mastrangelo mj. Cancer Res. 1988 Mar 15;48(6):1671-5. Cancer Res. 1988. PMID: 2830969

5

Active immunotherapy of human melanoma exploiting the immunopotentiating effects of cyclophosphamide.

Berd D, Mastrangelo MJ. Berd D, et al. Among authors: mastrangelo mj. Cancer Invest. 1988;6(3):337-49. doi: 10.3109/07357908809080657. Cancer Invest. 1988. PMID: 3167614

6

Expression of cytokine mRNA in human melanoma tissues.

Lattime EC, Mastrangelo MJ, Bagasra O, Li W, Berd D. Lattime EC, et al. Among authors: mastrangelo mj. Cancer Immunol Immunother. 1995 Sep;41(3):151-6. doi: 10.1007/BF01521340. Cancer Immunol Immunother. 1995. PMID: 7553683

7

Activation markers on T cells infiltrating melanoma metastases after therapy with dinitrophenyl-conjugated vaccine.

Berd D, Maguire HC Jr, Mastrangelo MJ, Murphy G. Berd D, et al. Among authors: mastrangelo mj. Cancer Immunol Immunother. 1994 Sep;39(3):141-7. doi: 10.1007/BF01533378. Cancer Immunol Immunother. 1994. PMID: 7923243

8

Melanoma and vitiligo: immunology's Grecian urn.

Berd D, Mastrangelo MJ, Lattime E, Sato T, Maguire HC Jr. Berd D, et al. Among authors: mastrangelo mj. Cancer Immunol Immunother. 1996 Jun;42(5):263-7. doi: 10.1007/s002620050280. Cancer Immunol Immunother. 1996. PMID: 8706046 Review. No abstract available.

9

Active specific immunization in the treatment of patients with melanoma.

Mastrangelo MJ, Maguire HC Jr, Sato T, Nathan FE, Berd D. Mastrangelo MJ, et al. Semin Oncol. 1996 Dec;23(6):773-81. Semin Oncol. 1996. PMID: 8970602 Review.

10

Treatment of metastatic melanoma with autologous, hapten-modified melanoma vaccine: regression of pulmonary metastases.

Berd D, Sato T, Cohn H, Maguire HC Jr, Mastrangelo MJ. Berd D, et al. Among authors: mastrangelo mj. Int J Cancer. 2001 Nov;94(4):531-9. doi: 10.1002/ijc.1506.abs. Int J Cancer. 2001. PMID: 11745440 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

195 results

Search Page